FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375839920> ?p ?o ?g. }

• W4375839920 abstract "<p>Background: In acute exacerbations of chronic obstructive pulmonary disease (AECOPD), hypercapnia (raised arterial partial pressure of carbon dioxide, PₐCO₂) is associated with worse clinical outcomes, including death. Nasal high flow (NHF) therapy is a common method of administering oxygen therapy in hypoxic respiratory failure, yet its effect on PₐCO₂ in COPD are uncertain. Aims: To investigate the effects of NHF therapy in people with COPD. Methods: Two randomised controlled trials (RCTs) were undertaken to investigate the effect of NHF on transcutaneous partial pressure of carbon dioxide (PtCO₂) in COPD: one comparing different flow rates (45 L/min, 30 L/min and 15 L/min) to breathing room air as a control in 48 participants with stable COPD, and another comparing NHF against non-invasive ventilation (NIV) in 24 stable COPD patients with chronic hypercapnia. Two further studies tested the feasibility of undertaking multicentre RCTs utilising different applications of NHF in COPD: one in 100 patients (20 in New Zealand, 80 in the United States) using NHF at home for 30 days following hospital discharge to determine patterns of use and rates of hospital readmission, and another in the Emergency Department (ED) to test whether a pre-specified standard protocol for managing acute hypercapnic respiratory failure (AHRF) could be followed. Finally, another RCT compared the tolerability and change in PtCO₂ of a dual NHF/NIV device to a standard NIV device in people with chronic respiratory disorders including COPD. Results: In stable COPD, the mean (95% CI) change in PtCO₂ at 20 min was −0.6 mm Hg (−1.1 to 0.0), P = 0.06; −1.3 mm Hg (−1.9 to 0.8), P < 0.001; and −2.4 mm Hg (−2.9 to −1.8), P < 0.001; for NHF at 15 L/min, 30 L/min and 45 L/min, respectively, compared with room air. In stable COPD with chronic hypercapnia, the mean (SD) reduction in PtCO₂ at 60 min from baseline with NHF was -2.5 mmHg (3.5) compared to -5.3 mm Hg (5.0) with NIV. The PtCO₂ change when analysed across all time points was lower using NIV than with NHF: -2.5mmHg (95% CI -4.5 to -0.5), P=0.016. In the international outpatient feasibility study, mean (SD) NHF use at home following hospital discharge was 1.6 (1.6) hours/day in the 20 NZ participants. The 30-day hospital readmission rate was 10% (95% CI 1.8 to 33.1). Recruitment in the US was unsuccessful, despite a 12-month extension, and no data was available. In the second feasibility study, 120 patients with AECOPD were reviewed over a 4-month period in ED. All 3 patients with AHRF received the standard of care protocol and in one there was significant deviation from the agreed protocol. There was no difference in tolerability between the dual NHF/NIV device and a standard NIV device on a 100mm visual analogue scale: mean difference - 1.3mm (95% CI -7.9 to 5.2, P=0.69), and a lower PtCO2 with the standard NIV device, mean difference -0.61mm Hg (95% CI -1.05 to -0.17, P=0.01). Conclusion: The small, flow-dependent reduction in PtCO₂ observed with the currently available NHF device across the range of flows used in clinical practice indicates that it is safe to use in COPD from a physiological perspective. The reduction on PtCO₂ with NHF was smaller than with NIV, however the difference was of uncertain clinical significance, suggesting NHF represents an alternative therapy for COPD patients with hypercapnia who cannot tolerate NIV, or during breaks from NIV. In NZ, it would be feasible to undertake an RCT using NHF in AECOPD patients discharged from hospital, but not those presenting to ED with AHRF. The recently developed dual NHF/NIV device had similar tolerability as a standard NIV device and there was no clinically significant difference in PtCO2. These findings suggest that NHF represents a therapeutic option for patients with COPD, with the dual NHF/NIV device demonstrating potential as a modality for delivering NHF in COPD patients with AHRF.</p>" @default.
• W4375839920 created "2023-05-10" @default.
• W4375839920 creator A5022166961 @default.
• W4375839920 date "2021-12-08" @default.
• W4375839920 modified "2023-10-16" @default.
• W4375839920 title "Nasal High Flow Therapy in Chronic Obstructive Pulmonary Disease" @default.
• W4375839920 doi "https://doi.org/10.26686/wgtn.17142059.v1" @default.
• W4375839920 hasPublicationYear "2021" @default.
• W4375839920 type Work @default.
• W4375839920 citedByCount "0" @default.
• W4375839920 crossrefType "dissertation" @default.
• W4375839920 hasAuthorship W4375839920A5022166961 @default.
• W4375839920 hasBestOaLocation W43758399201 @default.
• W4375839920 hasConcept C118552586 @default.
• W4375839920 hasConcept C126322002 @default.
• W4375839920 hasConcept C168563851 @default.
• W4375839920 hasConcept C177713679 @default.
• W4375839920 hasConcept C194828623 @default.
• W4375839920 hasConcept C197934379 @default.
• W4375839920 hasConcept C2776780178 @default.
• W4375839920 hasConcept C2777037550 @default.
• W4375839920 hasConcept C2778375690 @default.
• W4375839920 hasConcept C2780630273 @default.
• W4375839920 hasConcept C2780724011 @default.
• W4375839920 hasConcept C42219234 @default.
• W4375839920 hasConcept C534529494 @default.
• W4375839920 hasConcept C71924100 @default.
• W4375839920 hasConceptScore W4375839920C118552586 @default.
• W4375839920 hasConceptScore W4375839920C126322002 @default.
• W4375839920 hasConceptScore W4375839920C168563851 @default.
• W4375839920 hasConceptScore W4375839920C177713679 @default.
• W4375839920 hasConceptScore W4375839920C194828623 @default.
• W4375839920 hasConceptScore W4375839920C197934379 @default.
• W4375839920 hasConceptScore W4375839920C2776780178 @default.
• W4375839920 hasConceptScore W4375839920C2777037550 @default.
• W4375839920 hasConceptScore W4375839920C2778375690 @default.
• W4375839920 hasConceptScore W4375839920C2780630273 @default.
• W4375839920 hasConceptScore W4375839920C2780724011 @default.
• W4375839920 hasConceptScore W4375839920C42219234 @default.
• W4375839920 hasConceptScore W4375839920C534529494 @default.
• W4375839920 hasConceptScore W4375839920C71924100 @default.
• W4375839920 hasLocation W43758399201 @default.
• W4375839920 hasLocation W43758399202 @default.
• W4375839920 hasOpenAccess W4375839920 @default.
• W4375839920 hasPrimaryLocation W43758399201 @default.
• W4375839920 hasRelatedWork W2026095104 @default.
• W4375839920 hasRelatedWork W2088061681 @default.
• W4375839920 hasRelatedWork W2139213660 @default.
• W4375839920 hasRelatedWork W2415104966 @default.
• W4375839920 hasRelatedWork W2592969970 @default.
• W4375839920 hasRelatedWork W2972703765 @default.
• W4375839920 hasRelatedWork W2973614780 @default.
• W4375839920 hasRelatedWork W3154944956 @default.
• W4375839920 hasRelatedWork W3172127275 @default.
• W4375839920 hasRelatedWork W4232888950 @default.
• W4375839920 isParatext "false" @default.
• W4375839920 isRetracted "false" @default.
• W4375839920 workType "dissertation" @default.